Glutamate Excitotoxicity in Brain Metastases From Lung, Breast and Melanoma Treated With Stereotactic Radiosurgery

Condition(s) studied

Investigational drug(s) / intervention(s)

Stereotactic radiosurgery: Gamma Knife stereotactic radiosurgery (SRS-GK)

Blood samples: Serum Glu levels and Glu-regulation markers assessed prior to and following SRS-GK in BM or benign lesions or at baseline in non-BM patients.

Study summary

Brain metastases (BM) represents a devastating clinical reality, carrying an estimated survival time of less than one year. Number of reasons, including complicated tumor biology and difficulties in modeling metastatic cancer in brain microenvironment, do hinder research on this topic. BM are indeed the most frequent neoplasm in the central nervous system (CNS) and is estimated that up to 14% of all newly diagnosed cancers will metastasize to the brain. A number of reasons, including complicated tumor biology and difficulties in modeling metastatic cancer in brain microenvironment, do hinder research on this topic. Present knowledge regarding alterations in Glutamate (Glu) homeostasis and BM is poor. This study aims at investigating Glu balance in BM patients and providing supporting evidence to the identification of new putative biomarkers to be used as potential therapeutic targets.

Eligibility

Primary outcome measure(s)

• Serum markers determination in newly diagnosed BM (lung, breast and melanoma) patients, before SRS treatment. — Baseline (pre-SRS);
  GOT1, GPT and LDH levels and serum glutamate, aspartate and lactate levels. All measures in mg/dl.
• Serum markers determination in newly diagnosed BM (lung, breast and melanoma) patients, after SRS treatment. — Baseline (pre-SRS) and at 3, 6 and 9 months
  GOT1, GPT and LDH levels and serum glutamate, aspartate and lactate levels. All measures in mg/dl.
• Serum markers determination in melanoma, lung or breast cancer patients without BM. — Baseline
  Comparison of serum GOT1, GPT and LDH levels and serum glutamate, aspartate and lactate levels between BM and non-BM patients. All measures in mg/dl.
• Serum markers determination in patients carrying benign intracranial lesions before and after SRS treatment. — Baseline (pre-SRS) and at 3, 6 and 9 months
  Comparison of serum GOT1, GPT and LDH levels and serum glutamate, aspartate and lactate levels between BM and benign lesion patients. All measures in mg/dl.

Trial sites (1)

More IRCCS San Raffaele trials in Italy

Other trials for the same condition